Glypressin (terlipressin) / Ferring - LARVOL DELTA

DIFFERENTIAL EFFECTS OF VASOPRESSIN AND TERLIPRESSIN AS ADJUNCT VASOPRESSORS ON HEMODYNAMIC PARAMETERS IN PATIENTS WITH CIRRHOSIS AND SEPTIC SHOCK: FINAL RESULTS: FROM THE VITEL-C RANDOMIZED CONTROLLED TRIAL [NCT05315557] (AASLD 2025) - P=N/A | "In CIC with septic shock, vasopressin is comparable to terlipressin as an adjunct to norepinephrine in reversing shock. While terlipressin led to a faster reversal of shock, it was associated with a higher incidence of adverse events and rebound hypotension. A distinct biomarker profile was noted with vasopressin conferring greater reductions in ANG-1 and NGAL, whereas terlipressin increased NT-proBNP."

Clinical • Fibrosis • Hepatology • Hypotension • Immunology • Septic Shock • ANGPT1 • LCN2

Practice patterns in small emergency departments (EUSEM 2025) - "In one model was observed an increased waiting time and a higher percentage of patients in triage (21% versus 12.4%, with an average waiting time 10 minutes higher, p<0.01). In contrast, this model was associated with performing a wider range of interventions (STEMI thrombolysis, transfer in time for stroke thrombolysis, noninvasive ventilation, extraction of ocular, auricular and nasal foreign bodies, administration of tranexamic acid, terlipressin, octreotide, gastric lavage with noradrenaline, intraosseous infusions, fracture reduction and stabilization), requesting a lower number of pediatric specialist consultations (19.87% versus 47.01%, p<0.01) and transferring patients 2.46 times more frequently directly to a hED, instead of other sEDs (CI 1.66-3.64).The study proposes in-depth research on waiting time as a performance criterion for the sEDs, in balance with the type of interventions performed by the physician, in the context of the specific role of the..."

Cardiovascular • Musculoskeletal Diseases • Orthopedics • Pediatrics

Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis (clinicaltrials.gov) - P=N/A | N=40 | Not yet recruiting | Sponsor: General Hospital of Shenyang Military Region | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Cardiovascular • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension

Noradrenaline Versus Glypressin for Prevention of Hypotension After Deflation of Tourniquet in Knee Arthroplasty (clinicaltrials.gov) - P=N/A | N=135 | Completed | Sponsor: Tanta University | Recruiting ➔ Completed

Trial completion • Hypotension • Orthopedics

Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients (clinicaltrials.gov) - P4 | N=104 | Recruiting | Sponsor: Beijing Tsinghua Chang Gung Hospital

New P4 trial • Acute Kidney Injury • Hepatology • Liver Failure • Nephrology • Renal Disease • Transplantation

OCE-205 in rats and non-human primates: Pharmacokinetic and pharmacodynamic analysis. (PubMed, Curr Res Pharmacol Drug Discov) - "The preclinical results of OCE-205, with its demonstrated V1a selective partial agonist activity and potentially tolerable safety profile, suggest its potential utility for treatment of the cardiovascular complications of cirrhosis. Procedures were approved by the Ferring Research Institute (FRI) Institutional Animal Care and Use Committee (IACUC) on November 27, 2006 under protocol FRI 06-011, and by the Sinclair Research Center IACUC under protocol S11177."

Journal • PK/PD data • Preclinical • Acute Kidney Injury • Cardiovascular • Fibrosis • Hepatology • Hypertension • Immunology • Nephrology • Portal Hypertension • Renal Disease

OCE-205, a Selective V1a Partial Agonist, Reduces Portal Pressure in Rat Models of Portal Hypertension. (PubMed, J Exp Pharmacol) - "Data support OCE-205 as a promising candidate for further development. Procedures were approved by the Ferring Research Institute (FRI) Institutional Animal Care and Use Committee on July 13, 2011, under protocol FRI-07-0002."

Journal • Preclinical • Cardiovascular • Fibrosis • Hepatology • Hypertension • Immunology • Portal Hypertension

Methods Decreasing Bleeding in Open Myomectomy (clinicaltrials.gov) - P4 | N=105 | Recruiting | Sponsor: Cairo University

New P4 trial • Allergy • Immunology • Uterine Leiomyoma

Terlipressin HRS Benefit Sustained in Transplant Subgroup of CONFIRM Study (HCPLive) - '"Among transplant recipients, overall survival through 12 months of follow-up was numerically 11% higher for those treated with terlipressin versus placebo,' lead author K. Rajender Reddy, MD...said during a presentation of the results. 'Collectively, these data indicate that terlipressin treatment in patients with hepatorenal syndrome led to better long-term clinical outcomes in those who received a liver transplant.'"

Media quote

Noradrenaline Versus Glypressin for Prevention of Hypotension After Deflation of Tourniquet in Knee Arthroplasty (clinicaltrials.gov) - P=N/A | N=135 | Recruiting | Sponsor: Tanta University

New trial • Hypotension • Orthopedics

Terlipressin and Management of Hepatorenal Syndrome (Southern California Society of Gastroenterology (SCSG))

Live event

Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis (clinicaltrials.gov) - P=N/A | N=40 | Not yet recruiting | Sponsor: General Hospital of Shenyang Military Region | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Cardiovascular • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension

Expert Picks From the Liver Meeting, Part 1 (Gastroendonews) - "In this installment of 'Expert Picks,' Ashwani K. Singal, MD, MS...discusses five of this favorite abstracts presented at The Liver Meeting 2022."

Online posting

Laparoscopic myomectomy for large cervical/broad ligament fibroids: case series (ESGE 2022) - "Diluted Glypressin was injected in the plane between the myoma & the pseudocapsule...All specimens were found histologically benign. Conclusions Laparoscopic myomectomy seems to be a safe option in cases of large cervical/Broad ligament fibroids if done in suitable conditions."

Clinical • Urology • Uterine Leiomyoma

A Budget Impact Model for Terlipressin in Treating Bleeding Oesophageal Varices Patients in the Philippines (ISPOR 2022) - "Vasoactive agents such as terlipressin, somatostatin, and sandostatin are widely used for the treatment of BOV... With a population of 110 million in the Philippines, increasing the utilization of terlipressin in patients with BOV from 5% in Year 1 to 7% in Year 5resulted in cost savings of between ₱3.06 million (approximately 61,271 USD) and ₱4.53 million (approximately 90,706 USD) from Year 1 to Year 5. This translated to a Per Member Per Year (PMPY) of -₱0.04 (approximately 0.00 USD) and a Per Member Per Month (PMPM) of ₱0.00 (approximately 0.00 USD) in Year 5. Cost savings were driven mainly by the savings in drug costs and hospitalizations."

Clinical • HEOR • Gastroenterology

A Cost-Effectiveness Analysis for Terlipressin in Treating Bleeding Oesophageal Varices Patients in the Philippines (ISPOR 2022) - "Treatment with the three vasoactive agents were cost-effective with ICERs within the WHO-recommended cost-effectiveness thresholds. Among the three vasoactive drugs, terlipressin was the most cost effective with the lowest ICER when compared to placebo (₱216,555 or approximately 4,336 USD per QALY). One-way deterministic sensitivity analysis showed that our data was robust with ICER results driven by drug costs and length of treatment."

Clinical • HEOR • Gastroenterology

A Romanian study on the impact of glypressin in laparoscopic myomectomy (ISGE 2022) - "Statistically significant differences (P<0.05) were drawn out from the two groups in relation to Hb and Ht after LM both Hb and Ht were decreased. All things considered, one can infer that the impact of glypressin administration in haemorrhage control in uterine leiomyomas may provide new future approaches, with respect to its administration in gynaecological haemorrhagic pathologies."

Solid Tumor • Uterine Leiomyoma

Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis (clinicaltrials.gov) - P=N/A | N=40 | Not yet recruiting | Sponsor: General Hospital of Shenyang Military Region | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension

The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets (clinicaltrials.gov) - P=N/A | N=162 | Recruiting | Sponsor: Wael Elbanna Clinic

New trial • Uterine Leiomyoma

Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the US and Terlipressin Potential (PracticeUpdate) - "The authors mentioned that early treatment with terlipressin to reverse HRS and avoid respiratory failure is supported and recommended by experts around the world. Further studies are recommended to advance terlipressin as the first-line therapy for HRS–AK in the United States."

Online posting

A Romanian study on the impact of glypressin in laparoscopic myomectomy. (PubMed, Exp Ther Med) - "Statistically significant differences (P<0.05) were obtained between the two groups in terms of Hb and Ht; after LM both Hb and Ht were decreased. In conclusion, the impact of glypressin administration in hemorrhage control in uterine leiomyomas may establish new future perspectives, regarding its administration in gynecological hemorrhagic pathologies."

Journal • Hematological Disorders • Solid Tumor • Uterine Leiomyoma

[VIRTUAL] IMPACT OF GLYPRESSIN IN LAPAROSCOPIC MYOMECTOMY (ISGE-I 2020) - "The impact of glypressin administration in hemorrhage control in uterine leiomyomas may establish new future perspectives, regarding its administration in gynaecological hemorrhagic pathologies."

Gynecologic Cancers • Gynecology • Hematological Disorders • Oncology • Solid Tumor • Uterine Leiomyoma

Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis (clinicaltrials.gov) - P=N/A; N=40; Not yet recruiting; Sponsor: General Hospital of Shenyang Military Region; Trial completion date: Dec 2020 ➔ Dec 2022; Trial primary completion date: Dec 2020 ➔ Dec 2022

Clinical • Trial completion date • Trial primary completion date • Fibrosis • Gastroenterology • Hematological Disorders • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension

Slow infusion of furosemide and albumin with or without terlipressin safely mobilizes ascites and impacts hemodynamics and intestinal permeability in ACLF patients with organ failure(s) and improves 28-day survival (ILC 2017) - "SIFA(T) in ACLF with OF may modify deranged systemic hemodynamics, IP and improve survival"

Clinical • Oncology

Slowlow-dose continuous albumin, furosemide ± terlipressin and N-acetylcystine infusion in severe alcoholic hepatitis safely mobilizes ascites in acute on chronic liver failure with organ failure(s) and improves 28-day survival (ILC 2017) - "Top Down approach in SAH ACLF patients can safely mobilize ascites and may improve 28-day survival. HCV: DAA resistance and retreatment"

Clinical • Oncology